Vir Biotechnology
CA · 4 filings, 2025
Lobbying spend · 2025
$200K
to shape legislation
About the organization
Sotrovimab, sold under the brand name Xevudy, is a human neutralizing monoclonal antibody with activity against severe acute respiratory syndrome coronavirus 2, known as SARS-CoV-2. It was developed by GlaxoSmithKline and Vir Biotechnology, Inc. via Wikipedia ↗
1Lobbies on
Its filings list: Health Issues
2Through these firms · 1
FORBES-TATE
3Bills moving in its lanes
No bill names this company outright; these are recent bills in the sectors it lobbies.
- S 5225A bill to amend the Elementary and Secondary Education Act of 1965 to include certain curriculum expenses a…
- S 5232A bill to amend the Public Health Service Act to authorize rural residency planning and development grant p…
- S 5237A bill to require the Director of the National Institute of Allergy and Infectious Diseases to award a comp…
- S 5242A bill to provide for digital communication of prescribing information for drugs (including biological prod…
- HR 10033Rules for self-driving cars and emergency crews